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Abstract
In this article we describe the current use of recombinant activated
factor VII (rFVIIa; NovoSeven®) in trauma patients. Emphasis is
placed on current uses as defined by key studies, efficacy data,
and safety data. Most published studies in trauma patients are
retrospective case studies and reports, although an international,
double-blind, randomized, controlled, phase II study has been
conducted that reported on the efficacy of rFVIIa in reducing the
amount of blood products transfused in blunt trauma patients. That
study demonstrated the efficacy and safety profile of this
hemostatic agent as compared with placebo as adjunctive therapy
in the management of severe bleeding associated with trauma.
Further prospective, randomized, and placebo-controlled clinical
trials will yield more information on the role of rFVIIa in the
management of traumatic bleeding.
Introduction
Trauma mortality has been described to have a trimodal or
bimodal distribution [1-4]. Of trauma deaths 50% occur at
the scene of injury because of massive head injury or
exsanguination [3,4]. There is then a second peak, which
represents 30% of the deaths that occur early, half of which
are due to uncontrollable hemorrhage [3,4]. A third phase of
later deaths, related to multiple organ failure (MOF)
associated with prolonged shock, massive transfusion, and
infection [5,6], is also seen, although improvements in trauma
care have seen figures fall. Life-threatening traumatic
hemorrhage that occurs is often due to surgical and
coagulopathic bleeding. Successful surgical control of
bleeding has been assisted by the evolution and refinement
of angioembolization [5,6]. The coagulopathy of trauma has
remained problematic and its etiology is multifactorial,
involving hypothermia, acidosis, consumption of clotting
factors, and dilution [7,8]. If a patient develops the lethal triad
of hypothermia, acidosis, and coagulopathy, then surgical
control is less likely to be effective alone [9]. Coagulopathy in
trauma may also be due to traumatic brain injury, fat embolus
syndrome, or pre-existing comorbidities requiring oral anti-
coagulation. Attempts to minimize transfusion of blood and
blood products have led clinicians to look at alternate means
of restoring hemostasis [10].
Use of recombinant activated factor VII in trauma
Recombinant activated factor VII (rFVIIa; NovoSeven®; Novo
Nordisk A/S, Bagsværd, Denmark) has been used to control
life-threatening traumatic bleeding that has been uncorrected
by other means. rFVIIa acts to amplify coagulation at the local
site of injury where tissue factor and phospholipids are
exposed, accelerating the tissue factor-dependent pathway
and generating a thrombin burst along with platelet surface
interactions [11,12]. The first published account of the use of
rFVIIa in trauma was a case report from Kenet and coworkers
[13] published in 1999, documenting the first successful use
of rVIIa in a soldier with traumatic coagulopathy following a
high velocity gunshot wound to the inferior vena cava. The
first case report in the USA was that by O’Neill and
coworkers [14] published in 2002, which described the use
of rFVIIa in a patient sustaining multiple stab wounds who
was transfused with more than 100 units of blood before
receiving a single dose of rFVIIa. This patient’s coagulopathy
did resolve, but she later succumbed to sepsis.
In 2001 Martinowitz and coworkers [15] reported on the use
of rFVIIa in experimental grade V liver trauma in coagulopathic
swine. In this experimental model, in which liver packing was
combined with rFVIIa treatment, post-treatment blood loss
was significantly less and the prothrombin time decreased
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5 min after injection. However, in a later study with a similar
experimental model of liver trauma in noncoagulopathic swine,
rFVIIa alone, without liver packing, did not reduce blood loss
[16]. Thus, an experimental conclusion suggests first that
there is a need to establish surgical control of bleeding, which
should then be followed by adjunctive use of rFVIIa to aid in
the cessation of coagulopathic bleeding. There appeared to
be no role for rFVIIa in noncoagulopathic animals.
Treatment with rFVIIa is not currently licensed for use in
trauma patients. In 1999 the US Food and Drug
Administration approved rFVIIa for the treatment of
spontaneous bleeding in patients with hemophilia A or B and
in patients with known inhibitors to factor VIII or IX. In the
European Union, rFVIIa is also licensed for the treatment of
spontaneous and surgical bleeding in hemophilia A and B
with known inhibitors to factor VIII and IX, as well as for use in
the following indications: acquired hemophilia; patients with
congenital factor VII deficiency undergoing surgery or
invasive procedures; and patients with Glanzmann’s
thrombasthenia with antibodies to blood platelets,
glycoprotein IIb/IIa, or HLA. Its use in trauma patients has
been described, but currently there are no published
prospective randomized control trials documenting its
benefits. A summary of the current available literature on the
use of rFVIIa in trauma is given in Table 1. Most of the
published literature is limited to retrospective studies,
anecdotal reports, and abstracts (Table 1) [12-14,17-22].
The largest, most recent study is a double-blind, phase II,
multicenter, multinational, prospective, randomized controlled
trial of rFVIIa in trauma patients conducted during the period
2001-2003. The final results are yet to be published in full,
but the results were presented in part at the 6th World
Congress on Shock, Inflammation & Sepsis in Munich,
Germany (February 2004) and at the 25th International
Symposium on Intensive Care and Emergency Medicine in
Brussels, Belgium (March 2005) [23-25]. The final results will
be published in the Journal of Trauma in 2005.
In this study, trauma patients who received 6 units of red
blood cells (RBCs) within 12 hours of hospital admission
were randomized into the study; both blunt and penetrating
injuries were included, but those with major traumatic brain
injury were excluded. After being administered a further
2 units of RBCs, patients received either placebo or rFVIIa
given in three doses: first 200 µg/kg, followed by 100 µg/kg
at 1 hour, and an additional 100 µg/kg at 3 hours. There was
no significant difference in mortality between the group
treated with rFVIIa and the placebo group (Table 2). In blunt
trauma, RBC transfusion was significantly reduced with rFVIIa
compared with placebo (estimated reduction by 2.6 RBC
units;  P = 0.02), and the need for massive transfusion
(>20 units of RBCs) was reduced (14% versus 33% of
patients; P = 0.03), representing a relative risk reduction of
58%. In penetrating trauma, similar analyses revealed trends
toward reduced RBC transfusion with rFVIIa (estimated
reduction of 1.0 RBC units; P = 0.10) and massive
transfusion (7% versus 19%; P = 0.08). Trends toward
reductions in mortality and critical complications were
observed. Adverse events including thromboembolic events
were evenly distributed between treatment groups [23,24].
Table 1
Summary of the current literature published regarding the use of recombinant activated factor VII in trauma
Reported 
reduction in 
Patients Dose  transfusion  Mortality  Thrombotic 
Ref. (year) (n) Type of study Type of patients (µg/kg) requirements (deaths; n) complications
[13] (1999) 1 Case report Penetrating 60, 60 100% 0 None
[12] (2001) 7 Case series Blunt and penetrating 120–212 100% 3 None
[14] (2002) 1  Case report Penetrating 90 100% 1 None
[21] (2002) 19 Case series Blunt and penetrating 129 78% 6 1 DVT
[22] (2002) 18 Case series Blunt and penetrating 40 83% 5 1 IAT
[17] (2003) 5 Case series Blunt and penetrating 80–144 60% 2 None
[19] (2003) 21 Case series Multi-trauma and surgical 30–180 86% 5 None
[20] (2004) 29 Retrospective matched case series Blunt and penetrating 40 100% 11 None
[32] (2004) 24 Retrospective chart review Blunt and penetrating ? 100% 9 None
[18] (2004) 81 Retrospective cohort Blunt and penetrating 48–148 80% 47 None
Unpublished  277 Prospective phase II Blunt and penetrating 200, 100,  Decreased 69 None
(2004) 100
DVT, deep vein thrombosis; IAT, iliac artery thrombosis.S39
Although not statistically significant, there was also a trend
toward a reduced incidence of MOF and acute respiratory
distress syndrome. Furthermore, intensive care unit (ICU)-free
and ventilator-free days were more pronounced in the treated
blunt trauma group (Table 2).
To date, in the USA the largest series is that reported by
Dutton and colleagues [18], with more than 80 patients
studied, including a previous study of five patients [17]. In
their series the indications for use of rFVIIa included acute
post-traumatic hemorrhage, severe traumatic brain injury,
septic coagulopathy, and factor deficiencies. Most of the
successful anecdotal studies report on the use of rFVIIa in
similar patients, but often these patients have been found to
be unresponsive to conventional coagulant therapy before
rFVIIa use. Coagulopathy was reversed in 61 out of 81 cases
(75%), with 42% of patients surviving to hospital discharge
[18]. Although all patients in the study were found to have an
initial clinical improvement in coagulation, 24% developed
irreversible hemorrhagic shock, re-developed coagulopathy,
received an average of 54 units of RBCs, and died within a
few days of admission. Those patients who responded
received an average of 33 units of RBCs during their hospital
stay. The patients included in this study received FVIIa
relatively late in their clinical course, after an average
transfusion of 20 units of RBCs. Interestingly, patients with a
sustained hemostatic response were treated earlier than
were patients who did not respond (15 versus 26 units of
RBCs; P = 0.002). In this study, 59 patients received rFVIIa
within 24 hours of admission. The average time from
admission to dosage was 5.5 days in the remaining 22
patients (range 1–37 days). One of the current theories is
that rFVIIa works better when it is used earlier, because there
has been less dilution of platelets and fibrinogen earlier in the
course.
In 2002 Martinowitz and coworkers [21] reported on the use
of rFVIIa in 19 trauma patients, including patients from
previous reports [12,13]. Using one to three doses of rFVIIa,
cessation of hemorrhage was documented in 79% of
patients, transfusion requirements decreased, and 13/19
(68%) patients survived. In 2003, Eikelboom and coworkers
[19] reported a case series of 21 patients treated with rFVIIa
for life-threatening hemorrhage. Only three patients in this
study had a traumatic injury as the cause of hemorrhage.
Bleeding was noted to stop in 18 of the 21 patients. At the
American Association for the Surgery of Trauma meeting in
September 2004, Harrison and coworkers [20] presented a
retrospectively matched case series of 29 patients treated
with a lower dose of 40 µg/kg rFVIIa and demonstrated a
significant decrease in the number of packed RBCs trans-
fused, with no difference in mortality.
At the Eastern Association for the Surgery of Trauma meeting
held in January 2002, Sifri and coworkers [22] presented
retrospective data on the first 18 patients to receive rFVIIa at
the University of Medicine and Dentistry of New Jersey-
University Hospital. Five patients received rFVIIa for
coagulopathy and 13 for active hemorrhage. All patients
received a low dose (<50 µg/kg) of rFVIIa within the first
10 hours after injury [22]. Bleeding was controlled in 83% of
patients, and there was a reduction in the transfusion
requirements following the use of rFVIIa [22]. There was one
possible drug-related thrombotic complication noted in a
patient with underlying atherosclerotic disease of his iliac
arteries who underwent angiography for a pelvic fracture that
developed iliac artery thrombosis.
Based on the anecdotal data summarized above, Dutton and
colleagues are also administering rFVIIa earlier in each
patient’s clinical course and are studying the clinical markers
that might indicate futility of rFVIIa use. Their studies have
found that the most significant factor in determining whether
rFVIIa use will be futile is a patient’s pH [18]. In vitro testing
of rFVIIa has demonstrated that decreasing the pH from 7.4
to 7.0 reduced the activity of rFVIIa by over 90% [26].
Temperature was not found to adversely affect the activity of
rFVIIa [26]. In addition, at the University of Maryland three
independent predictors of futility of rFVIIa administration were
found to be a Revised Trauma Score less than 4.1,




Outcomes measured in a randomized controlled trial of recombinant activated factor VII
Blunt trauma Penetrating trauma
Outcomes rFVIIa Placebo P rFVIIa Placebo P
Mortality 25% 30% 0.58 24% 28% 0.69
MOF/ARDS 10% 23% 0.07 7% 17% 0.11
ICU-free days 13 8 0.18 24 20 0.26
Ventilation-free days 17 14 0.44 26 22 0.17
Both intensive care unit (ICU)-free and ventilator-free days were measured for 30 days. ARDS, acute respiratory distress syndrome; MOF, multiple
organ failure; rFVIIa, activated recombinant factor VII.S40
Dutton and colleagues [18] used rFVIIa in nine patients with
severe traumatic hemorrhage and coagulopathy from use of
warfarin. Five of the nine patients died, four from their
traumatic brain injury and one from MOF. In 2002, a report of
13 patients with an elevated international normalized ratio
(INR) secondary to warfarin use underwent treatment with
rFVIIa either for a critically prolonged INR of 10 or greater or
bleeding complications [28]. All patients were noted to
exhibit correction of coagulation parameters, and bleeding
complications were treated. A review of the use of rFVIIa to
reverse anticoagulant therapy was recently published [29];
however, data on the timing of treatment and standardized
dosing are lacking.
There have also been reports of patients receiving rFVIIa for
treatment of traumatic brain injury without prehospital use of
warfarin. Again, a clinical improvement in hemorrhage was
seen by Dutton and colleagues [18] in all 20 patients, but
there was a 75% mortality in this group, most likely
attributable to their brain injury. Similarly, another case series
of nine patients undergoing neurosurgical intervention, two
with coagulopathy and traumatic brain injury, three on
warfarin for atrial fibrillation and four with end-stage liver
disease, was reported in 2003 [30]. That study demonstrated
a clinical improvement in coagulation parameters with early
rFVIIa use before neurosurgical intervention [30]. There were
no procedural or operative complications, and no post-
operative hemorrhagic complications were reported.
Therapy with rFVIIa has also been used for septic
coagulopathy associated with MOF [18]. All patients clinically
stopped bleeding; however, the average prothrombin time
was only 14 s before treatment with rFVIIa. Three out of the
four patients survived. Similar findings were reported by
Holcomb and coworkers [31] in a case report of a patient
with septicemia.
Dose
Because of the off-label use of rFVIIa in trauma, the
appropriate dosing and repeat dosing is currently unknown.
The dosage of rFVIIa in the trauma literature varies from 40 to
212 µg/kg (Table 1) [12-14,17-22,32]. The double-blind
study in patients with blunt and penetrating trauma used an
initial dose of 200 µg/kg, followed by an additional 100 µg/kg
if bleeding persisted and a further 100 µg/kg if required, but
there is currently no label for rFVIIa in trauma [23,25]. The
recommended dose in hemophilia is 90 µg/kg. When it is
administered to a trauma patient, nonsurgical bleeding
treated with rFVIIa appears to be controlled relatively quickly
(within 10–15 min) or stops at once, but if bleeding is noted
to resume then additional doses have been given. The serum
half-life of rFVIIa is 2.7 hours. The more common dosing for
acute traumatic hemorrhage is 50–100 µg/kg. More recently
doses as low as 10 µg/kg have been described [28]. Most of
the lower doses have been used for reversal of anti-
coagulation and intracranial bleeds [28,33].
Currently, there are too few data to speculate on a minimum
effective dose in trauma, particularly given all the potential
variables and confounders in this mixed patient group.
Perhaps the greatest reported drawback of treatment with
rFVIIa is the cost. An average dose of 4.8 mg (50 µg/kg in a
70 kg adult) costs US$3000–4000. Most agree that there is
a financial burden of cost for rFVIIa in a trauma population,
which is difficult to quantify secondary to its immeasurable
benefit in terms of patient survival.
Laboratory monitoring
Coagulation parameters have not been well studied with use
of rFVIIa. At the University of Maryland, the typical prothrombin
time decreased from 17.5 to 9.3 s and the INR dropped from
2.2 to 0.58 [18]. Thromboelastogram recordings before and
after rFVIIa use have been utilized to determine the quality of
the clot formed. Thromboelastogram demonstrated an
improvement in the time to onset of clotting, the rate of clot
formation, the maximum amplitude, the time to reach stable
clot, and the rate of subsequent clot lysis [18]. There are no
conclusive studies recommending the best therapeutic
monitoring modality for rFVIIa, so should the need for repeated
dosing be based on clinical response? Platelets are required
for the formation of a stable clot and appear to be a necessary
component of rFVIIa-induced coagulation. Dutton and
coworkers observed several patients with platelet counts
below 50,000 cells/l who did not clinically form clot after
rFVIIa administration until they received a platelet transfusion.
The authors recommended that the platelet count at the time
of FVIIa administration be verified, and that platelets be given
concurrently if the count is under 50,000 cell/l [18].
In their case series Martinowitz and coworkers [12] reported
that the median fibrinogen level in patients before rFVIIa admini-
stration was 150 mg/dl (25–75 quartile range: 110–195 mg/dl),
whereas the normal range is 200–400 mg/dl. Despite the
lowered fibrinogen levels, adequate hemostasis was achieved
in these patients.
Safety
Because of a current lack of level I evidence, potential risks,
benefits, and costs should be considered before rFVIIa is
used. During the period 1996–2000 more than 140,000
doses of rFVIIa were administered for hemophilia, with a
complication rate of less than 0.02% [34]. An adverse effect
is the potential for thromboembolism, which has been
associated with advanced atherosclerotic disease, septi-
cemia, crush injury, and disseminated intravascular coagu-
lation. The two main safety concerns specifically in trauma
patients are an increased risk for deep vein thrombosis and
pulmonary embolism, and increased microvascular
coagulation and subsequent acute lung injury and MOF.
A recent study conducted by Roberts and coworkers [34]
suggested that inappropriate thrombosis occurring after
rFVIIa administration is unlikely to be due to the need for
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exposed tissue factor at the site of vascular injury as well as
activated platelets. Despite theoretic concerns, no increased
incidence of prothrombotic complications has been reported
[35]. In a recently published, matched, case–control
investigation into the use of rFVIIa to manage intractable
blood loss after cardiac surgery [36], 51 treated patients had
undergone a variety of procedures, including – either singly
or in combination – coronary artery bypass grafting (CABG)
surgery (n = 21), valve replacement and/or repair (n = 28),
ascending aorta or aortic arch replacement and/or repair
(n = 15), complex congenital abnormality repair (n = 8), heart
transplantation (n = 4), or insertion of a left ventricular assist
device (n = 1). In this series, the rFVIIa dosing was 4.8 mg
(approximately 70 µg/kg) intravenous bolus for patients with
severe, uncontrolled blood loss and 2.4 mg (approximately
35 µg/kg) intravenous bolus for patients with less severe,
controlled blood loss. In the 21 patients who underwent
CABG surgery, rFVIIa therapy was not associated with an
increased risk for myocardial infarction, end-organ failure, or
death, but it was associated with some measures of morbidity
(renal dysfunction and length of ICU and hospital stay). This
increased morbidity in patients undergoing CABG may be
due to the effects of rFVIIa therapy, the greater blood loss in
the rFVIIa-treated patients, or a combination of the two
factors.
The safety profile reported by Roberts and coworkers [34]
has not validated a substantial risk for diffuse thrombosis. In
the series reported by Martinez and coworkers [21] there
was one deep vein thrombosis. No thrombotic events were
reported by Eikelboom and coworkers [19]. One iliac artery
thrombosis in patients with aortoiliac disease was reported
by Sifri and coworkers [22]. In studies utilizing rFVIIa for a
variety of indications, the incidence of thrombotic
complications is slightly higher than when trauma patients
are studied alone, suggesting that despite the slightly higher
risk for a hypercoaguable state in trauma patients an
increased rate of thrombotic complications has not been
observed.
Conclusion
There remain numerous open questions about the use of
rFVIIa in the setting of trauma. What is the best timing for
administration? How many units of blood and/or blood
products should be transfused? What is the proper dose?
How many doses should be used? What are the indications
and contraindications of rFVIIa use? When is the use of
rFVIIa futile? Although rFVIIa has been shown to be a
valuable tool in the armamentarium of trauma resuscitation
with rescue from coagulopathic bleeding, reduction in
intracranial hemorrhage, and reversal of anticoagulants, more
prospective studies are needed to confirm that rFVIIa use is
safe. There is no doubt that a large prospective, placebo-
controlled trial will answer some as yet unanswered
questions in trauma patients as well as delineate the drug’s
anticipated efficacy.
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